Safety and Pharmacokinetics Study of YYB101 in Advanced Solid Tumors Patients Who Are Refractory to Standard Therapy

Phase 1 Completed 39 enrolled CellabMED

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and maximum tolerated dose (MTD) of YYB101, HGF-neutralizing humanized Mab, in advanced solid tumors patients who are refractory to standard therapy.

Timeline

Start: 2015-07-13
Primary completion: 2018-07-04
Completion: 2018-07-04

Publications

Kim ST, Hong JY, Park SH, Park JO, Park YW, Park N, Lee H, Hong SH, Lee SJ, Song SW, Kim K, Park YS, Lim HY, Kang WK, Nam DH, Lee JW, Park K, Kim KM, Lee J. First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients. Ther Adv Med Oncol. 2020 Jun 2;12:1758835920926796. doi: 10.1177/1758835920926796. eCollection 2020.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	UMIKIBART	Monoclonal antibody	0.3 mg/kg	Intravenous
Subject	UMIKIBART	Monoclonal antibody	1 mg/kg	Intravenous
Subject	UMIKIBART	Monoclonal antibody	3 mg/kg	Intravenous
Subject	UMIKIBART	Monoclonal antibody	5 mg/kg	Intravenous
Subject	UMIKIBART	Monoclonal antibody	10 mg/kg	Intravenous
Subject	UMIKIBART	Monoclonal antibody	20 mg/kg	Intravenous
Subject	UMIKIBART	Monoclonal antibody	30 mg/kg	Intravenous

Safety and Pharmacokinetics Study of YYB101 in Advanced Solid Tumors Patients Who Are Refractory to Standard Therapy

Summary

Timeline

Publications

Drugs

Indications